Two years of gene therapy dealmaking

AAVs have continued to dominate gene therapy deals in the past two years, but many new deals are moving beyond the naturally occurring vectors that populate most of the therapeutic pipeline to engineered constructs. Deal activity for non-viral approaches is also picking up.

Of the 97 gene therapy deals recorded in BioCentury’s BCIQ database from Jan. 1, 2020 through Oct. 22,  2021, 56 (58%) involved adeno-associated viral (AAV) vectors, of which at least 13 deals focus on AAVs engineering...